Health Care/Hospital
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
* IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life * IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering * IMG-007 is being evaluated in two global proof-of-concept trials SAN DIEGO,...
2023-08-18 19:00
4508
Nature-inspired pressure sensing technology aims to transform healthcare and surgical robots
NUS researchers take a leaf out of nature's book to develop 'eAir' — an
aero-elastic sensor that revolutionises the way pressure is detected
SINGAPORE, Aug. 18, 2023 /PRNewswire/ -- Researchers at the National
University of Singapore
2023-08-18 17:54
1551
United Imaging Healthcare delivers its 2023 Half-Year report, with revenue growth of 26.35% in the first half of 2023
SHANGHAI, Aug. 18, 2023 /PRNewswire/ -- United Imaging Healthcare (SSE:688271), a global innovator in cutting-edge medical imaging and radiotherapy equipment, has unveiled its highly anticipated 2023 half-year report, revealing robust growth. The report indicates that the company achieved5.27 bil...
2023-08-18 17:29
2433
JinMed (NASDAQ: ZJYL) Rings the Nasdaq Stock Market Closing Bell on August 17
CHANGZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ: ZJYL), the world's leading provider of rehabilitation equipment, rang the bell at the New York Stock Exchange by its Chairman and CEOWang Erqi on August 17, to celebrate the Com...
2023-08-18 11:36
4024
QiLu Pharmaceutical's Iruplinalkib Phase III INSPIRE Study Researched Primary Endpoint and was Selected for 2023 WCLC Oral Presentation
JINAN, China, Aug. 18, 2023 /PRNewswire/ -- August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical's iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral presentation at th...
2023-08-18 09:50
2266
Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.
* Analyzed the FDA FAERS data…to compare the thrombotic AEs of Hemlibra vs. FVIII replacements. YONGIN, South Korea, Aug. 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced on August 17, 2023 that it has presented the results of analyzing and...
2023-08-18 08:58
2059
Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet
SHANGHAI, Aug. 18, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced the publication inThe Lancet of the full data from the NeflgArd Phase 3 trial with Nefecon® in...
2023-08-18 08:41
2017
The Global Medical Robotics Conference 2023: A Deep Dive into China's Booming Surgical Robotics Landscape
BEIJING, Aug. 17, 2023 /PRNewswire/ -- The groundbreaking Global Medical Robotics Conference 2023 will be held inBeijing on September 8, 2023. This unprecedented event brings together a wide range of surgical robotics from around the world, making it the first of its kind globally. The conference...
2023-08-18 02:08
1518
BoomerangFX expands into Australian Market Driven by Growing Demand for Aesthetic Medicine Services in Asia Pacific
Responding to Growing Customer Demand – Cloud-Based Clinic Software, Digital Marketing & eLearning Provider Makes Significant Advances in the Australian Market TORONTO and MIAMI, Aug. 17, 2023 /PRNewswire/ -- BoomerangFX, a global provider of Software as a Service (SaaS), specializing in compreh...
2023-08-18 00:01
1369
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy
WUHAN, China and SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused byND1 ...
2023-08-17 21:00
1224
Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis
SHANGHAI, HANGZHOU, China and WILMINGTON, Del., Aug. 17, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, today announced the successful enrollment of the first patient in the phase 3 clinical study for MH004 Cream targeting mild to moderate a...
2023-08-17 19:00
4159
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
* Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐ Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including pat...
2023-08-17 18:00
4130
2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib
* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctDNA) testing in detecting EGFR exon 20 insertion (Exon20ins) mutations. * Both tumor tissue-based and plasma ctDNA testing can be used to identify patients who may benefit from treatment with su...
2023-08-17 17:10
1971
Capco's Singapore 2023 insurance survey highlights opportunities for insurers to use innovative data and personalization strategies to meet evolving customer needs
Consumers favor more personalized products and are willing to share additional personal data with insurers to secure benefits, including an enhanced claims process and cheaper premiums Insurers need to consider long-established customer imperatives such as affordability, value for money and a pr...
2023-08-17 10:00
1634
Novo Holdings participates in $290m strategic financing of Sangon Biotech
COPENHAGEN, Denmark, Aug. 17, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced it has participated in a $290 million (USD) strategic financing round of Sangon Biotech. Sangon is a leading provider of life science tools and services, enabling scient...
2023-08-17 09:44
1952
TraceLink Collaborates with GS1 US to Author GS1 US Addendum Guidance and XML Examples for GS1 US DSCSA Implementation Guideline R1.3 to Support EPCIS Data Exchange
Publication of the GS1 standard guidelines and technical examples provide a strong foundation to help companies accelerate their network connectivity and EPCIS-based sTI/TS data exchange to meet forthcomingNovember 2023 DSCSA deadlines. BOSTON, Aug. 17, 2023 /PRNewswire/ -- TraceLink Inc., the l...
2023-08-17 09:35
1247
Global Leading Health Company JUNG KWAN JANG Participates in "William Jones Cup" after 4-year Gap
TAIPEI, Aug. 17, 2023 /PRNewswire/ -- Korea Ginseng Corporation's JUNG KWAN JANG basketball team will compete in the William Jones Cup International Basketball Tournament to be held inTaiwan from August 12. They will represent South Korea as the men's basketball team and compete against foreign t...
2023-08-17 08:00
2231
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-08-17 08:00
2891
Oncoclínicas Group generated record earnings in the second quarter of 2023, R$309 million and a net profit of R$35 million
Efficient management of working capital explains a large part of the cash flow performance. Net income grew 51% (31% organically) while the Ebitda Ex-LTIP (excluding only the non-cash impact of the long-term incentive plan) reached R$268 million, 109% greater than the same period last year SÃO PA...
2023-08-16 19:00
1643
"Pink Walk 2023" - signature charity walk of Hong Kong Breast Cancer Foundation is making a comeback on 15 October at the Peak
"Step Up for Breast Health"! HONG KONG, Aug. 16, 2023 /PRNewswire/ -- The Hong Kong Breast Cancer Foundation (HKBCF), is delighted to announce that its annual signature fundraising event"Pink Walk 2023" is making a comeback on 15 October 2023 (Sunday) at The Peak,Hong Kong Island. Themed "Step U...
2023-08-16 17:16
2218
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
9822
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
6268
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
5661
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
4606
